Oxervate Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increasing diagnosis of neurotrophic keratitis, limited availability of effective corneal repair therapies, advancements in recombinant protein development, growing ophthalmology specialty care access, regulatory approvals for orphan drugs.

The growth in the forecast period can be attributed to expansion of regenerative ophthalmology research, rising investments in rare eye disease therapeutics, increasing adoption of biologics in ophthalmology, growing awareness among eye care professionals, expansion of specialty pharmacy distribution. Major trends in the forecast period include increasing adoption of recombinant growth factor therapies, rising focus on rare ophthalmic disease treatments, expansion of targeted corneal regeneration solutions, growing emphasis on precision biologics manufacturing, enhanced cold-chain handling for biologic eye drops.

The rising incidence of eye inflammation disorders is expected to drive the growth of the Oxervate market in the future. Eye inflammation disorders are conditions in which the tissues of the eye become swollen and irritated, often resulting in pain, redness, and vision problems. The increasing prevalence of these disorders is due to factors such as environmental pollution, longer screen time, allergies, and an aging population. Oxervate helps treat eye inflammation disorders by delivering a recombinant form of nerve growth factor (NGF), which promotes the healing of corneal tissue, reduces inflammation, and improves nerve function, thus restoring the eye’s protective barrier. For example, in May 2024, according to GOV.UK, a UK-based government website, over 8.9 million vision outpatient attendances were recorded in England for the financial year ending 2023, representing a rate of 15,362 per 100,000 population, marking an increase compared to the previous year. As a result, the growing incidence of eye inflammation disorders is contributing to the growth of the Oxervate market.

The increasing geriatric population is expected to accelerate the growth of the Oxervate market in the coming years. The geriatric population refers to individuals aged 65 and older, often facing age-related health challenges. The rise in this population is attributed to advancements in healthcare, improved living standards, and better access to medical treatments. Oxervate benefits the geriatric population by promoting corneal nerve regeneration and reducing the risk of corneal damage in individuals with neurotrophic keratitis, a condition frequently found in older adults due to age-related changes in the nervous system. For example, in July 2024, according to the UK Parliament's House of Commons Library, a UK-based government administration, it was reported that 12.7 million people in the UK were aged 65 or older in 2022, representing 19% of the total population. This number is projected to rise to 22.1 million by 2072, making up 27% of the country’s population. Therefore, the growing geriatric population is driving the growth of the Oxervate market.

The increasing adoption of personalized medicine is also expected to boost the growth of the Oxervate market. Personalized medicine is a healthcare approach that tailors treatment plans and therapies based on an individual’s unique biological characteristics, daily habits, and environmental factors to improve treatment effectiveness and patient outcomes. The widespread use of personalized medicine is driven by advancements in genomics, increased availability of patient-specific data, and the development of targeted therapies. Oxervate supports personalized medicine by focusing on specific biomarkers and customizing treatment plans for individual patients, particularly in managing rare eye diseases like neurotrophic keratitis, thus enhancing treatment effectiveness based on each patient’s unique condition and response. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from six in 2022. Therefore, the growing adoption of personalized medicine is helping drive the growth of the Oxervate market.

Major companies operating in the oxervate market are Dompé Farmaceutici S.p.A.

North America was the largest region in the oxervate market in 2025. The regions covered in the oxervate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oxervate market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the oxervate market by increasing costs associated with imported recombinant protein inputs, specialized biologic manufacturing equipment, sterile packaging materials, and cold-chain logistics infrastructure. These impacts are most pronounced in North America and Europe, where advanced biologics production and cross-border sourcing of pharmaceutical inputs are common. Higher tariffs are contributing to elevated production and distribution costs, which can influence pricing and reimbursement dynamics for rare disease therapies. However, tariffs are also encouraging localized biologics manufacturing, regional supplier partnerships, and increased investments in domestic production capabilities to ensure long-term supply stability.

The oxervate market research report is one of a series of new reports that provides oxervate market statistics, including oxervate industry global market size, regional shares, competitors with a oxervate market share, detailed oxervate market segments, market trends and opportunities, and any further data you may need to thrive in the oxervate industry. This oxervate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oxervate (cenegermin-bkbj) is a prescription ophthalmic solution used to treat neurotrophic keratitis, a rare degenerative condition affecting the cornea. It contains cenegermin, a recombinant human nerve growth factor (rhNGF), which aids in the repair and regeneration of corneal tissue by promoting the survival and growth of corneal nerves.

The primary clinical indications for Oxervate are neurotrophic keratitis and dry eye disease (DED). Neurotrophic keratitis is a rare, progressive corneal disease caused by nerve damage, leading to impaired healing, chronic dryness, and the potential for ulceration. Oxervate is distributed through various channels, including retail pharmacies and online pharmacies, and is used by a wide range of end users, such as hospitals, ophthalmology clinics, and home care providers.

The oxervate market consists of sales of eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.